Hemogenyx Pharmaceuticals (LSE:HEMO) EBIT: £-9.54 Mil (TTM As of Dec. 2025)

What is Hemogenyx Pharmaceuticals EBIT?

Hemogenyx Pharmaceuticals LSE:HEMO +5.55% 31 EBIT is £-9.54 Mil as of Dec. 2025. GuruFocus rates LSE:HEMO with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Hemogenyx Pharmaceuticals's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was £-4.65 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was £-9.54 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Hemogenyx Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2025 was -149.03%. Hemogenyx Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -465.57%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Hemogenyx Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -17.86%.

Hemogenyx Pharmaceuticals (LSE:HEMO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Hemogenyx Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

	ROC % (Q: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2025 )	+	Invested Capital (Q: Dec. 2025 ))	/ count )
=	-4.166 * ( 1 - 0% )	/	( (2.945	+	2.646)	/ 2 )
=	-4.166	/	2.7955
=	-149.03 %

where

	Invested Capital		(Q: Jun. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	3.101	-	0.909	-	( 0.227	-	max(0, 1.323	-	0.57	+	0.227	))
=	2.945

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4.176	-	0.965	-	( 1.586	-	max(0, 1.47	-	2.035	+	1.586	))
=	2.646

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Hemogenyx Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2025		Q: Dec. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-9.302	/	( ( (2.193 + max(-0.566, 0))	+	(1.803 + max(-0.579, 0)) )	/	2 )
=	-9.302	/	( ( 2.193	+	1.803 )	/	2 )
=	-9.302	/	1.998
=	-465.57 %

where Working Capital is:

	Working Capital		(Q: Jun. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.343	+	0	+	-1.1102230246252E-16)	-	(0.909	+	0	+	0)
=	-0.566

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.009	+	0	+	0.44)	-	(0.965	+	0	+	0.063)
=	-0.579

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Hemogenyx Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2025 )
	=	-9.538	/	53.407
	=	-17.86 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemogenyx Pharmaceuticals EBIT Related Terms

Hemogenyx Pharmaceuticals EBIT Historical Data

* Premium members only.

The historical data trend for Hemogenyx Pharmaceuticals's EBIT can be seen below:

Hemogenyx Pharmaceuticals EBIT Chart

Hemogenyx Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

-2.51

-3.99

-6.38

-5.35

-9.54

Hemogenyx Pharmaceuticals Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
EBIT	Get a 7-Day Free Trial															-2.22	-2.67	-2.68	-4.89	-4.65

LSE:HEMO vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Hemogenyx Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hemogenyx Pharmaceuticals EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemogenyx Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hemogenyx Pharmaceuticals's EV-to-EBIT falls into.

Save Embed

31GF Score

Hemogenyx Pharmaceuticals PLC LSE:HEMO

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Hemogenyx Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-9.54 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of £-9.54 Mil mean?

Hemogenyx Pharmaceuticals (LSE:HEMO) has a EBIT of £-9.54 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Hemogenyx Pharmaceuticals.

Is Hemogenyx Pharmaceuticals' EBIT too high?

Hemogenyx Pharmaceuticals' current EBIT is £-9.54 Mil. Overall, Hemogenyx Pharmaceuticals has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.

How does Hemogenyx Pharmaceuticals' EBIT compare to VRTX and REGN?

Hemogenyx Pharmaceuticals' EBIT of £-9.54 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals's current EBIT is £-9.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Hemogenyx Pharmaceuticals stock overvalued right now?

Hemogenyx Pharmaceuticals (LSE:HEMO) has a current EBIT of £-9.54 Mil. The current EBIT is £-9.54 Mil. Hemogenyx Pharmaceuticals' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Hemogenyx Pharmaceuticals (LSE:HEMO), the current EBIT is £-9.54 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemogenyx Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies LSE:POLB LSE:COIL LSE:SBTX LSE:SAR LSE:4BB LSE:AREC LSE:IMM LSE:FARN LSE:APTA LSE:BVXP VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 6 Heddon Street, London, GBR, W1B 4BT

Website https://www.hemogenyx.com

Hemogenyx Pharmaceuticals PLC is clinical-stage biotechnology focused on the discovery, development and commercialisation of treatments relating to the treatment of blood cancers, certain solid cancers, autoimmune diseases, and viral infections. The products under development are designed to address a range of problems that occur with current standard of care treatments. The Group has one reportable segment, the discovery, development, and commercialisation of treatments relating to blood and immune system disorders and viral infections, and administrative functions in the United Kingdom. It has its presence in United Kingdom; and United States.

31GF Score

Get the complete analysis for LSE:HEMO

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£7.80

Price

View LSE:HEMO Analysis

See EBIT data for all stocks →